BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization
Kashyap MK, Amaya-Chanaga CI, Jones H, et al.
Key Points:
- Correlative studies from phase I study of monotherapy cycle of BMS-936564 (an anti-CXCR4 IgG4 antibody) in 3 relapse/refractory CLL subjects
- All subjects showed early (within 4 hours) and sustained leukocytosis throughout four weeks of monotherapy with BMS-936564
- All subjects showed CXCR4 down-regulation in peripheral CLL cells, with no change in normal B cells
- One subject showed significant increase in percentage of apoptosis
- All patients showed significant decrease in lymphadenopathy size with median decrease of 59.83% (range: 55.6-72%)
- All three subjects tolerated infusions well with no evidence of side effects or toxicities.
Implications:
- BMS-936564 infusion induces specific leukemia cell mobilization, objective decrease in lymphadenopathy bulk and phenotypic changes associated with CXCR4 down-regulation in peripheral leukemia cells
- BMS-936564 potential new target for drug therapies against minimal residual disease.
View the original abstract on the ASH website.
